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TM wclcomc ut~late on the AIDS research situation nut 
tugcther for &A by W.J.W. Morrow of ID&C 
Pharmaceuticals rnkcs the form of a series of 6 papers from 
leading groups covering the currcnc clinical and social 
situation, all aspects of the HIV infection and life cycle 
pracess, the inmune response to the virus and recent attempts 
at vaccine development. In 19118, a set of AlBS reviews was 
published in Scientific American. At that time author’s views, 
which no doubt reflected the collective feelings in the scientific 
community, were essentially upbeat and optimistic, The 
massive research effort urrdcrway would in the end prevail. 
After all this was not anything as intractable as cancer; merciy 
an infectious disease with a clearly defined and cultureable 
agent. This assurance was bolstered by the detailed knowlcdgc 
then uncovered of the virus structure, genetic and physical, 
and its life cycle, Many of the early questions had been 
answered and on the basis of evidence available plausible 
hypotheses had been advanced for the rest. 
The feeling pervading this BBA issue is more uncertain and 
pessimistic. Depressingly little movement towards a cure can 
be detected in the intervening period. In addition, many of 
those assumptions about the way HlVs 1 and 2 go about their 
fatal business have not been validated, In fact several have 
been partially undermined. 
Take the straight forward notion that the AIDS condition 
is caused by I-iIV attacking and destroying the CD4-bearing T- 
helper lymphocytes, a view fostered by the experimentally 
verified fact that the virus binds to and infects any cell 
sporting these receptor molecules at their surface via a direct 
interaction with CD4. However, as discussed in Sattentau’s 
article, although the population of T-helper cells declines 
during the course of the disease, very few in fact carry the 
virus. Also, cells which do not make CD4 are now known to 
be infected. Mow does HIV get into these? Kieber-Emmons, 
Jarneson and Marrow in their review on the role of the 
gp120-CD4 interface report that mutations can be inserted 
into the viral coat protein which do not affect its ability to 
bind to CD4 but which do destroy virus infectivity, Does HIV 
therefore have a second cell surface ligand and is this more 
important for the net p;rthologicnl effect? These new 
questions arechallenging thr old dogmn and the picture is ICSS 
certain than before. 
The fact that patients die because they cannot defend 
themselves nyainst secondary infections is obvious. But is this 
only due to the lack of an adequate number of T-helper cells? 
In their paper, Evans and Levy describe evidence which 
demonstrates a reduced ability of circulating natural killer 
cells and of aberrant functioning of phngocytic cells in AIDS 
patients, Volbcrding and McCutchnn in their stimulating 
ovcrvicw of medical aspects which introduces the series 
describe data indicating that the opportunistic infection to 
which patients are susceptible very much depends upon the 
original route of infection with HIV - astranyc finding if only 
T-helper cells are involved. 
Perhaps the least glooniy of the collection is the paper by 
Kieber-Emmons et al. dealing with the structural, 
immunological and pathological facts relating to virus- 
receptor interaction. Here there have been important 
developments. Soluble CD4, which is the extracellular portion 
of this membrane glycoprotein, has been shown to inhibit 
viral infection in vitro. When tested in vivo however it was 
quickly cleared from the blood stream. Genetic manipulation 
was applied to the problem and a soluble 
CD4-immunoglobulin heavy chain chimera was produced. 
This survives for much longer in the circulation of patients 
and is currently under clinical trial. The results are eagerly 
awaited for this test will reveal whether or not the currently 
held image of the disease has feet of clay. If HIV pathology 
is really mediated by an alternative and as yet unknown cell 
surface receptor, then soluble CD4 will have little effect on the 
progress of AIDS in patients. 
One serious difference between this and the earlier series is 
the presence of an article in the latter on available drugs and 
strategies for the develogmsnc of new ones to interfere with 
viral reproduction and sprebd. In the BBA collection there are 
only 2 paragraphs on chemotherapeutic aspects and only AZT 
is mentioned. This is sureIy a major omission, difficult to 
understand in light of the readable vaccine review by Zhou 
Alzhcitner’r Discnsz CAD) is a brain-spcoific diseaxc that 
results in scvcrc eoynitivc impairment nird ix ChurWrritretl by 
an obundnnse of nwitic piques and ncurofibrillary ranglcx 
and rhc sclcctive dcgeocrution QP ncrvc cells located mainly in 
the: ccrcbral CQrrcx snd hippocampus, The condition, its 
possible eauscs and physiaehemical manifestations arc: 
summarized in 30 short Chi~ptCrs yrollpd into 7 major 
thcmcs; (i) fhc molsculnr biology of rhc amyloid fibril 
prrcursar protein, (ii) the eharacreriratiarr of paired helical 
filonrcnrs, (iii) animal models and species spccifieiry far AD, 
(iv) regional specificity of the pathology, (v) degcncrntion and 
neuropktsticity, (vi) IIOn-ncuronal invobdcment in AR 
pathology, and (vii) genetics of AD. Molecular handles for the 
study of AD are the accumulation of A4 protein and 
neurofibrillnry tangles, and a major proportion of the book 
concerns the role of the A4, or beta protein, in AD. Possible 
cxplnnrtionn 0I’ the weumulnrion caf the protein fragment are 
clixcwwd in relatioli to the t&t that the ame protein ix PQo~~ci 
abundtmtly in ik~n’% #ynclrwrr~c brain (triramy 21) and the 
gene for the A4 prcctrrser is located on chromosome 21. The 
presence of p&cd hclicwl filaments msy bc a further example 
of the accumtrtation af aberrant pQ)ypCptidfm psrriet&irly ax 
rhcy appear tQ be I’lagged far potentinl destruction by their 
conjugntion with llbi~uitin, (icnc dosage, csntrd ST gene 
cxprcsian and prstein etltsboiirm are areas prabed 8s 
causative: lactsrs far thsre changes in brnin protein 
biochemistry. The presence of a protcase inhibitor sequence 
on the A4 preeursar ir auggcstiw that proteolytie functians 
mny be impurtant in RD. Scrnpic with the ‘inkc~ivc’ protein 
or prion and in~llse rrisomy 16 are prcdcntcd as possible 
modctr of neurod~g~l~cra~~on. Howctdcr it remains to be 
clarified whcthcr the accumulated aberrant polypcptidcs so 
characteristic of wurodsgznrrntion are the direct causal 
agents of AD, or whether these apparently incompletely 
degraded polypeptidcs are non-paihological symptoms of an 
unidcntificd ncurotaxic factor which also provokes their 
accumulation. 
A.R, Migkiss 
Transmembrane SignaIling, Intracellulnr Mcssengw and Implications for Drug Development; Edited by Stefan 
R. Nahorski; John Wiley, Chichestcr, 1990; xvi + 248 pages; E39.50 
As an overfrequent participant at scientific meetings, I do not 
care to have the repayment of my fare or accomodation being 
made condit.ional on the delivery of a script. I sense that many 
others who delight in presenting their work and ideas for 
discussion at meetings share my dissatisfaction with a form of 
publication whicn is generally inaccessible to most readers 
(i,e. rarely do these appear in a sequence of a serial 
publication), almost invariably out of date (two years is not 
unusual) and very expensive. There are exceptions of course 
and on occasion I have been happy to arrive at important 
meetings or exotic places with my ticket underwritten by a 
paper. Similarly, I can imagine most of those invited to speak 
at the annual Biological Council Symposium on Drug Action 
in the Spring of 1989 were also happy to arrive, script in hand. 
The reason for this is that the meeting was held in the 
magnificent 18th century lecture theatre ai, the Royal 
Institution near Piccadilly in London, made famous in earlier 
times by such as Humphrey Davy, Michael Faraday and John 
(‘Blue Sky’) Tyndall (and which should not to be confused 
with the Royal Society whose facilities pale in comparison). 
So, what have WC got? The volume at just under 250 pages 
comprises 14 chapters and encompasses most of the main 
areas of intcrcst expressed in the title. Mainly this means the 
mechanisms by which the concentrations of cyclic AMP and 
Ca2’ insi,de cells arc regulated and appropriately the 
consider-ation of subsequent events (e.g. regulation of protein 
phosphorylation and dephosphorylation) is excluded. There is 
nothing on retinal transduction and there are a few other 
obvious omissions. A number of leading laboratories arc 
represented by authorship and doubtless anyone working in 
the area will find something of interest. More than this, a 
number of the chapters are well introduced with nice historical 
sections (e.g. Regan, Caron and Lefkowitz on adrenergic 
receptors, Buckley on muscarinic receptors). At a timr when 
all is being swept aside by cloning techniques, I suspect that 
these introductory words will have more staying power than 
anything else and in this respect the artic!es will serve those 
students who require a historical background. The best 
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